Why the study?
Does radiochemotherapy (Bleomycin/Adriamycin + radiotherapy) improve histological outcomes in prostatic cancer patients?
Does radiochemotherapy (Bleomycin/Adriamycin + radiotherapy) improve histological outcomes in prostatic cancer patients?
Early pilot data suggests radiochemotherapy produces variable histological responses in prostate cancer, warranting further randomized studies.
Answers are grounded in this paper and cite their sources.
Variable histological responses in this small case series leave open radiochemotherapy efficacy in prostate cancer; randomized trials needed.
Antiandrogen therapy has been widely used for prostatic cancer, yet many authors have reported on the limited efficacy of hormonal therapy for this disease. The present report is based on an histological evaluation of chemotherapy and radiotherapy in combination for prostatic cancer. To determine the usefulness of this combined therapy, 15 prostatic cancer patients were treated with a combination of Bleomycin and Adriamycin (BA therapy), or with only Adriamycin. Radiotherapy was administered to all cases. Twelve of the 15 patients were evaluable histologically with effects ranging from Grade I to Grade IV in Shimosato's classification. We conclude that further investigation, including a randomized study of hormonal therapy, is necessary.
No takes yet. Share an insight, caveat, or question.
Uyama et al. (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: